Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | CA1 | P00915 | 5/20 | 0.56 |
| ▸ | CA2 | P00918 | 5/20 | 0.56 |
| ▸ | CA9 | Q16790 | 5/20 | 0.56 |
| ▸ | CA12 | O43570 | 4/20 | 0.56 |
| ▸ | MMP1 | P03956 | 1/20 | 0.55 |
| ▸ | MMP2 | P08253 | 1/20 | 0.55 |
| ▸ | MMP9 | P14780 | 1/20 | 0.55 |
| ▸ | MMP8 | P22894 | 1/20 | 0.55 |
| ▸ | MMP13 | P45452 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | DHFR | P00374 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL634085 | 0.81 | ALDH1A1 (0.79) | ALDH1A1MAPTSMN1; SMN2CA1CA2 | |
| SCHEMBL23345377 | 0.81 | ALDH1A1 (0.67) | ALDH1A1MAPTSMN1; SMN2CA1CA2 | |
| SCHEMBL15840367 | 0.81 | ALDH1A1 (0.67) | ALDH1A1MAPTSMN1; SMN2CA1CA2 | |
| SCHEMBL6952974 | 0.80 | ALDH1A1 (0.66) | ALDH1A1MAPTSMN1; SMN2CA1CA2 | |
| SCHEMBL10258693 | 0.80 | ALDH1A1 (0.56) | ALDH1A1MAPTSMN1; SMN2CA1CA2 | |
| SCHEMBL1479992 | 0.79 | ALDH1A1 (0.59) | ALDH1A1MAPTSMN1; SMN2CA1CA2 | |
| SCHEMBL2333640 | 0.79 | ALDH1A1 (0.59) | ALDH1A1MAPTSMN1; SMN2CA1CA2 | |
| SCHEMBL4781214 | 0.79 | CA1 (0.61) | ALDH1A1MAPTSMN1; SMN2CA1CA2 | |
| SCHEMBL12169369 | 0.79 | ALDH1A1 (0.68) | ALDH1A1MAPTSMN1; SMN2CA1CA2 | |
| SCHEMBL3834643 | 0.79 | ALDH1A1 (0.80) | ALDH1A1MAPTSMN1; SMN2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476456-B2 | Process for the preparation of 4-(imidazol-1-yl)benzenesulfonamide derivatives | PALAU PHARMA, S.A. (ES) | 2013-07-02 | — | — | US | claimed |
| US-20090012307-A1 | Process for the Preparation of 4-(imidazol-1-yl)benzenesulfonamide Derivatives | PALAU PHARMA, S.A. (ES) | 2009-01-08 | — | — | US | claimed |
| EP-1424329-B1 | PROCESS FOR THE PREPARATION OF 4-(IMIDAZOL-1-YL)BENZENESULFONAMIDE DERIVATIVES | PALAU PHARMA SA (ES) | 2008-05-28 | — | — | EP | claimed |
| US-20040242872-A1 | Method of preparing 4-(imidazole-1-yl)benzenesulphonamide derivatives | PALAU PHARMA, S.A. (ES) | 2004-12-02 | — | — | US | claimed |
| EP-1424329-A1 | METHOD OF PREPARING 4-(IMIDAZOLE-1-IL)BENZENESULPHONAMIDE DERIVATIVES | J. Uriach & Cia. S.A. (ES) | 2004-06-02 | — | — | EP | claimed |
| EP-4719413-A1 | INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF | Animol Discovery, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260092070-A1 | INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF | ANIMOL DISCOVERY INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20250162989-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. | 2025-05-22 | — | — | US | disclosed |
| WO-2024246837-A1 | INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF | ANIMOL DISCOVERY, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-20240262792-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. | 2024-08-08 | — | — | US | disclosed |
| CN-117836270-A | USP30 inhibitors and uses thereof | 文森雷生物科学股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| EP-4305021-A1 | USP30 INHIBITORS AND USES THEREOF | Vincere Biosciences, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| US-6638921-B1 | Pharmaceutically acceptable derivatives thereof Cx, R1 and R2 being as defined in the disclosure may be used to inhibit the activity of HIV integrase. | PHARMACOR INC. (CA) | 2003-10-28 | — | — | US | disclosed |
| WO-2003082881-A2 | PYRIDOXAL-5-PHOSPHATE DERIVATIVES AS HIV INTEGRASE INHIBITORS | PROCYON BIOPHARMA INC. (CA) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003037887-A1 | THERAPEUTIC ISOQUINOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-05-08 | — | — | WO | disclosed |
| US-6548512-B1 | Pyrazole derivatives such as 1-(3-amidinophenyl)-3-methyl-2-((5-(2'-aminosulfonylphenyl-1-yl)pyrimidin-2 -yl)aminocarbonyl)pyrazole; treating thromboembolic disorders | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-15 | — | — | US | disclosed |
| CN-1246847-A | Nitrogen containing heteroaromatics as factor Xa inhibitors | DU PONT MERCK PHARMA (US) | 2000-03-08 | — | — | CN | disclosed |
| US-6020357-A | CARDIOVASCULAR DISORDERS; ANTCOAGULANTS | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-02-01 | — | — | US | disclosed |
| EP-0946508-A1 | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS | Du Pont Pharmaceuticals Company (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998028269-A1 | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012307-A1 | Process for the Preparation of 4-(imidazol-1-yl)benzenesulfonamide Derivatives | IL1B, IL1A, TBXAS1 | ALDH1A1 373/4885MAPT 4025/4885SMN1; SMN2 2591/4885 |
| US-20040242872-A1 | Method of preparing 4-(imidazole-1-yl)benzenesulphonamide derivatives | IL1B, IL1A, IRAK1 | ALDH1A1 251/4885MAPT 4155/4885SMN1; SMN2 3307/4885 |
| US-20260092070-A1 | INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF | JAK1, JAK3, JAK2 | ALDH1A1 1691/4885MAPT 3322/4885SMN1; SMN2 4009/4885 |
| US-20250162989-A1 | USP30 INHIBITORS AND USES THEREOF | USP30, USP28, USP1 | ALDH1A1 2021/4885MAPT 2434/4885SMN1; SMN2 1580/4885 |
| US-20240262792-A1 | USP30 INHIBITORS AND USES THEREOF | USP30, USP28, USP1 | ALDH1A1 2021/4885MAPT 2434/4885SMN1; SMN2 1580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.